CTRI/2019/03/018026CompletedPhase 4
Clinical utility of L-Arginine as an add on therapy in patients of hypertension
Pravara Institute Of Medical Sciences Loni0 sites180 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 180
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •All the patients of hypertension taking anti- hypertensive drugs since last sixth months
- •Adult patients between 18-60years
- •Patients of either gender
- •Patient ready to give written informed consent and willing to participate in the trial
Exclusion Criteria
- •Patient suffering from Gestational hypertension
- •Patients suffering from hypertension with Brain disorders
- •Patients with history of thyroid disorders and taking anti-epileptic medication
- •Patients on chronic medications other than anti-hypertensive drugs
- •Use of any drug that may affect nitric oxide synthesis (nitrates, CNS depressant, steroids)
- •Patients with history of Diabetes mellitus
- •Renal failure patients
- •Patient with history of ischemic heart disease, Transient ischemic attack (TIA), Stroke or peripheral arterial disease
- •Patients with history of recurrent herpes
- •Patients with history of Cancer treated with radiotherapy or chemotherapy during the last year
Investigators
Similar Trials
Recruiting
Phase 3
Effect of arginine on chronic anal fissureIRCT20190712044182N1Iran University of Medical Sciences76
Not yet recruiting
Phase 3
The effect of L-arginine in non-alcoholic fatty liverIRCT20230409057859N1Shahid Beheshti University of Medical Sciences60
Completed
Not Applicable
Arginine in COVID-19 patientsCTRI/2022/01/039549Clinical Research Centre Dept of Physiology74
Completed
Phase 3
Investigating the effectiveness of L-arginine in reducing duration of hospitalization and pain intensity of children with sickle cell disease compared to placebo.Sickle cell disease.Other sickle-cell disorders with crisisD57.81IRCT20170112031891N2Ahvaz University of Medical Sciences120
Active, not recruiting
Phase 1
Pharmacological intervention study with L-arginin in prevention of diabete type II in patients affected by metabolic syndrome.EUCTR2005-004639-24-ITOSPEDALE S. RAFFAELE294